Medical visits for chemotherapy and chemotherapy-induced neutropenia: A survey of the impact on patient time and activities

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Fortner, Barry V ^a   Tauer, Kurt ^a   Zhu, Ling ^a   Okon, Theodore A ^b   Moore, Kelley ^b   Templeton, Davis ^c   Schwartzberg, Lee ^a  

^a WEST CLINIC   (United States)

^b Supportive Oncology Services Incorporated   (United States)

^c Supportive Oncology Services Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AMBULATORY CARE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; DRUG INDUCED DISEASE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MODEL; NEUTROPENIA; TIME;

ACTIVITIES OF DAILY LIVING; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; QUALITY OF LIFE; RECOMBINANT PROTEINS; SICKNESS IMPACT PROFILE; TIME FACTORS;

EID: 3042718940     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-22     Document Type: Article

References (27)

1. Ashley J, Taylor D, Houts A, Fortner B, Durrence H: The experience of chemotherapy-induced neutropenia: quality-of-life interviews with adult cancer patients [abstract]. Oncol Nurs Forum 2003, 30:120.
2. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002, 95:155-163.
3. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997, 34 Suppl 2:13-19.
4. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vozelgang NJ: Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000, 5:353-360.
5. Houston D: Supportive therapies for cancer chemotherapy patients and the role of the oncology nurse. Cancer Nurs 1997, 20:409-413.
6. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997, 13:63-74.
7. Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100:228-237.
8. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri JD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000, 18:3558-3585.
9. Neupogen (filgrastim) prescribing information. Thousand Oaks, Calif: Amgen; 2002.
10. Neulasta (pegfilgrastim) prescribing information. Thousand Oaks, Calif: Amgen; 2002.
11. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart M: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003, 14:29-35.
12. Lindley C, Vasa S, Sawyer WT, Winer EP: Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998, 16:1380-1387.
13. Meehan K, Tchekmedyian S, Ciesla G, Kallich J, Erder MH, Smith R: The burden of weekly epoetin alfa injections to patients and their caregivers [abstract]. Proc Am Soc Clin Oncol 2003, 22:543.
14. Moore K, Fortner B, Okon T: The impact of medical visits on patients with cancer [abstract]. Oncol Nurs Forum 2003, 30:128.
15. Hinds G, Moyer A: Support as experienced by patients with cancer during radiotherapy treatments. J Adv Nurs 1997, 26:371-379.
16. Junor EJ, Macbeth FR, Barrett A: An audit of travel and waiting times for outpatient radiotherapy. Clin Oncol (R Coll Radiol) 1992, 4:174-176.
17. Goodwin JS, Hunt WC, Samet JM: Determinants of cancer therapy in elderly patients. Cancer 1993, 72:594-601.
18. Guidry JJ, Aday LA, Zhang D, Winn RJ: Transportation as a barrier to cancer treatment. Cancer Practice 1997, 5:361-366.
19. Payne S, Jarrett N, Jeffs D: The impact of travel on cancer patients' experiences of treatment: a literature review. Eur J Cancer Care 2000, 9:197-203.
20. Jacobsen PB, Meade CD, Stein KD, Chirikos TN, Small BJ, Ruckdeschel JC: Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol 2002, 20:2851-2862.
21. Moore KA: Breast cancer patients' out-of-pocket expenses. Cancer Nurs 1999, 22:389-396.
22. Pearce S, Kelly D, Stevens W: 'More than just money'-widening the understanding of the costs involved in cancer care. J Adv Nurs 2001, 33:371-379.
23. Houts PS, Lipton A, Harvey HA, Martin B, Simmonds MA, Dixon RH, Longo S, Andrews T, Gordon RA, Meloy J: Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 1984, 53:2388-2392.
24. Glynn-Tucker EM: A multidisciplinary performance improvement project for the management of febrile neutropenia [abstract]. Oncol Nurs Forum 2002, 29:354.
25. Maxwell C, Winkler L, Lottenberg M: Nurse driven neutropenia management guidelines: improving patient outcomes through evidence-based practice [abstract]. Oncol Nurs Forum 2002, 29:371.
26. Anastasia PJ, Blevins MC: Outpatient chemotherapy: telephone triage for symptom management. Oncol Nurs Forum 1997, 24 Suppl 1:13-22.
27. Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH: Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Huntingt) 2002, 16 Suppl 10:117-124.